Biostage, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 7.98 million compared to USD 4.87 million a year ago. Basic loss per share from continuing operations was USD 0.79 compared to USD 0.55 a year ago.
Harvard Apparatus Regenerative Technology Inc.
Equities
HRGN
US09074M2026
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.64 USD | +1.54% | +7.76% | -47.09% |
1st Jan change | Capi. | |
---|---|---|
-47.09% | 37.22M | |
+8.46% | 220B | |
+14.38% | 194B | |
+26.90% | 149B | |
+33.90% | 113B | |
+4.45% | 65.75B | |
+15.11% | 52.43B | |
+1.93% | 50.47B | |
-4.22% | 38.54B | |
-1.75% | 34.12B |
- Stock Market
- Equities
- HRGN Stock
- News Harvard Apparatus Regenerative Technology Inc.
- Biostage, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021